CERENION closes a 500,000€ seed investment round in its brain monitoring business

Cerenion Oy, the next-generation brain monitoring company from Oulu, has announced the completion of a 500,000€ seed investment round in its business. The sum invested by Butterfly Ventures and Icebreaker.vc will enable Cerenion to expand its multisite clinical study program, seek regulatory certification for its technology and bring it to market.

The company develops the world’s frst practical method for measuring the brain function of intensive care patients. Its C-Trend™ solution aims to reveal the status of the brain as one simple score – at the bed-side and without requiring any changes to the care of the patient.

‘Cerenion is a unique combination of deep research and a great complementary team that is creating a leader of a completely new category in healthcare. Their product will greatly help doctors in their work and save lives, ’says Riku Seppälä, Partner at Icebreaker.vc.

‘We liked the team a lot. They’re a great combination of different kinds of skills and expertise. Furthermore, they’re very execution focused and they have taken the case far already before the investment, both in terms of product as well as clinical validation. Superb team together with strong IP, clear market entry path and scalable business model are the ingredients that Cerenion is made of,’ adds Juho Risku, Managing Partner at Butterfly Ventures.

The prospects for Cerenion are very promising. Its technology provides potentially invaluable information for the intensive care market, which is estimated at 200 billion euros worldwide.

Read more here.

Contact person

Timo Koskela
CEO and Co-founder
040 5773 706
timo.koskela@cerenion.com

 

 

← Back to news & blogs